Ali Rizvi to Cardiovascular Diseases
This is a "connection" page, showing publications Ali Rizvi has written about Cardiovascular Diseases.
Connection Strength
2.033
-
Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. Expert Rev Cardiovasc Ther. 2022 Jul; 20(7):515-527.
Score: 0.487
-
Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues. Int J Mol Sci. 2021 Nov 15; 22(22).
Score: 0.465
-
Non-glycemic effects of pioglitazone and incretin-based therapies. Expert Opin Ther Targets. 2013 Jul; 17(7):739-42.
Score: 0.259
-
Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health. Biochim Biophys Acta Mol Basis Dis. 2022 12 01; 1868(12):166559.
Score: 0.124
-
The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. Int J Mol Sci. 2021 Jun 21; 22(12).
Score: 0.113
-
Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochim Biophys Acta Mol Basis Dis. 2021 08 01; 1867(8):166148.
Score: 0.112
-
Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2019 Feb; 12(2):129-143.
Score: 0.096
-
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018 09; 1864(9 Pt B):2814-2821.
Score: 0.091
-
Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults. Clin Cardiol. 2014 Sep; 37(9):517-22.
Score: 0.071
-
A review of the cardiovascular and anti-atherogenic effects of ghrelin. Curr Pharm Des. 2013; 19(27):4953-63.
Score: 0.063
-
Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr Pharm Des. 2013; 19(21):3858-68.
Score: 0.063
-
Recognition and implications of the metabolic syndrome. J S C Med Assoc. 2004 Apr; 100(4):107-12.
Score: 0.034
-
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin Drug Saf. 2022 Jan; 21(1):9-20.
Score: 0.029
-
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism. 2020 10; 111:154343.
Score: 0.027